NCT00961233View on ClinicalTrials.gov

Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

August 31, 2011

Study Completion Date

November 30, 2011

Conditions
Eosinophilic Esophagitis
Interventions
DRUG

inhaled/swallowed budesonide

medication will be nebulized and then swallowed

DRUG

viscous/swallowed budesonide

viscous suspension of budesonide will be swallowed

Trial Locations (1)

27599

University of North Carolina, Chapel Hill

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER